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ABSTRACT
Repeated-sprint training (RS, short-duration sprints at supramaximal intensities 
interspersed with brief recoveries) is a time-saving metabolically effective strategy 
whose effects on bone are unknown. Bone metabolism is a finely regulated process 
profoundly affected by exercise as assayable by studying specific systemic (e.g., 
hormones, cytokines) and bone-derived molecules (e.g., bone markers, miRNAs). 
Aim of this study was to determine the effect of a 8-week repeated-sprint on 
circulating levels of fracture risk-associated miRNA. Blood was collected from 9 
subjects performing RS 3 times/week (EXP) and 9 age-matched inactive controls 
(CTRL) before the start of the protocol (T0) and after 4 (T1) and 8 weeks (T2). 
The relative expression of miR-21-5p, miR-23a-3p, miR-24-3p, miR93-5p, miR-100-
5p, miR-122-5p, miR-124-3p, miR-125b-5p, miR-148a-3p, miR-637 was assayed by 
real-time PCR by the 2-ΔΔCT method (housekeeping: miR-425-5p, miR-484). Serum 
concentrations of bone markers (DKK1, sclerostin, osteoprotegerin, osteocalcin, 
osteopontin), cytokines (IL-1β, TNFα), and metabolic hormones (leptin, insulin, PTH) 
were assayed by multiplex assay. miR-637 and miR-124-3p were undetectable. In 
CTRL miRNA levels remained unchanged. In EXP miR-21-5p remained unchanged. 
Compared to T0 miR-23a-3p and miR-24-3p were significantly decreased at T1 and 
T2, also compared to CTRL, miR-100 was significantly decreased at T2, miR-122-5p, 
miR-125-5p, and miR148a-3p were significantly decreased at T1, while miR-93-5p 
was significantly increased at T1. None of the metabolic hormones was affected by the 
intervention while, among the bone markers, DKK1, osteocalcin and sclerostin were 
slightly but significantly decreased. In conclusion, an 8-week repeated-sprint training 
downregulates the expression of circulating miRNA associated with fracture risk.
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INTRODUCTION
Among the many factors influencing morbidity and 
mortality with increasing age, maintenance of healthy 
bone is an important variable for general health and 
quality of life. This is especially true since bone exerts 
important endocrine functions, besides the classical 
ones (e.g., locomotor, protection, mineral reservoir, 
hematopoiesis) [1–4]. Indeed, the bone involvement 
within the energy metabolism is evidenced in several 
physiological (e.g., exercise) and pathological (e.g., 
metabolic syndrome, diabetes) conditions in which by 
affecting bone metabolism impacts on energy metabolism 
and vice versa [5, 6].
Osteoporosis is a worldwide health problem [7] and 
physical exercise is a valid and effective to prevent or 
counteract osteoporosis in all life stages in both women 
and men [8, 9].
Sprint running, as well as endurance running which 
is known to improve BMD, are both weight-bearing 
activities. The differential bone-related effects result 
mainly from differences in energy substrate utilization and 
specific metabolic adaptations [10]. Repeated-sprint (RS), 
characterized by short-duration sprints at supramaximal 
intensity interspersed with brief recovery (interval 
training), has been proposed as a time-efficient strategy 
and effective and viable alternative to endurance training 
protocols [11, 12]. As for other kinds of interval trainings, 
encouragement to RS training in healthy and diseased 
people is supported by several social and psychological 
reasons [13]. First, being remarkably time efficient, it fits 
better with Western society’s time-poor lifestyle. Second, 
it may be more attractive for individuals (e.g., sedentary) 
who difficulty handle exercise sessions perceived 
monotonous and too long. Third, RS training results in 
the maintenance of and improvement in muscular strength 
since it requires a high level of muscular power. As such, 
it is considered a reliable and time-efficient strategy to 
stimulate metabolic adaptations in skeletal muscles [13].
The scientific interest around the interval training is 
growing due to the evidences about its benefits in several 
pathological conditions, besides the well-known benefits 
of physical activity in general. High-intensity training 
programs have been demonstrated to be beneficial in 25 
medical conditions, including cardiovascular disease, 
stroke, hypertension, cancer, and type 2 diabetes [14]. 
Interestingly, beside the possible preventive effects of 
physical activity, and particularly of interval training, 
in cancer onset, this kind of physical activity has been 
indicated as very effective in improving life quality 
in tumor survivors and to reduce the fatigue sensation 
following chemotherapy [15].
Among the interval training typology, RS training 
has been shown to exert multiple beneficial effects in 
healthy and diseased human subjects, including improved 
cardiorespiratory fitness, glycemic control [16], heart rate 
[17], and adiposity [18]. However, no information are still 
available about the effect of RS training on bone metabolism.
Classical and last-generation biochemical markers 
of bone turnover are exceptional tools for monitoring the 
effects of exercise protocols on metabolism and endocrine 
function of bone. They give an instantaneous picture of 
acute or established metabolic responses of the bone to a 
specific stimulus, before the architectural modifications 
ascertainable through radiographic techniques (e.g., dual-
energy X-ray absorptiometry [DXA]) [19]. However, the 
stimulus should exceed a threshold in intensity and duration 
before changes in circulating marker concentration can be 
appreciated. Changes in bone turnover markers may be 
preceded by changes in even more sensitive markers, such 
as microRNAs (miRNAs) [20, 21].
miRNAs are short (about 18 nucleotides) endogenous 
non-coding RNAs that regulate gene expression post-
transcriptionally. They target complementary mRNAs 
and induce their degradation. A single miRNA affects 
the expression of hundreds of genes [22]. miRNAs are 
also released into the circulation and their level changes 
with the multiple biologic adaptive responses to specific 
environmental conditions. Hence, circulating miRNAs 
provide a useful tool for studying the biological effects of 
interventions such as exercise and diet [23].
Several miRNAs regulate osteoblastogenesis and 
osteoclastogenesis by modulating the expression of 
key factors regulating these two processes and many of 
them have the potential for use as biomarkers of bone 
health status or therapy monitoring [24]. Indeed, altered 
expression of specific miRNAs has been associated with 
fracture risk and metabolic disorders of bone [20, 21]. This 
knowledge could be applied to diagnostic and therapeutic 
purposes [25]. 
However, the knowledge of the modulatory effects 
of exercise protocols on miRNAs associated with bone 
turnover and fracture risk is still very limited. This 
connection, although theoretically obvious, has been only 
suggested, or even speculated, but, to our knowledge, it 
has never been tested [26, 27]. This is of particular interest 
since, being miRNA biomarkers of early response, once 
clearly depicted their physiology, they would be applied 
in routine settings to verify the response to a specific 
intervention. Based on this background, with this study we 
aimed at determining the effects of an 8-week RS training 
protocol in healthy, young physically active males on the 
expression profile of selected fracture-risk-associated 
miRNAs, as well as on bone and energy metabolism 
markers, as compared to age-matched controls.
RESULTS
Figure 1 presents the changes in the panel of 
miRNAs assayed. These are the main findings: i) miR-
21-5p was stable; ii) miR-23a-3p and miR-24-3p were 
decreased at T1 and T2 compared to T0 and to CTRL; iii) 
Oncotarget18031www.oncotarget.com
Figure 1: Changes in fracture risk-associated circulating miRNAs. The figure shows the changes in the profile of circulating 
miRNA associated with fracture risk before (T0), during (T1), and after (T2) an 8-week repeated-sprints training protocol in the experimental 
group (orange blocks) and the controls (violet blocks). The relative expression of target miRNA is normalized to miR-425-5p and miR-484, 
here considered as housekeeping. The mean T0 values of the CTRL group were set at 1. Blocks indicate the ranges, central lines indicate 
the mean values. Asterisks indicate significant intergroup differences at a specific time point (*p <  0.05; **p <  0.01; ***p <  0.001). Symbols 
on bars indicate within-group difference vs. T0 ($p <  0.05; $$p <  0.01; $$$p <  0.001) and vs. T1 (§p <  0.05; §§p <  0.01; §§§p <  0.001).
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miR-100 was decreased at T2 compared to T0; iv) miR-
122-5p, miR-125-5p, and miR-148-3p were decreased at 
T1 and then recover to baseline at T2; iv) miR-93-5p was 
increased by the intervention.
More in detail, none of the miRNAs analyzed at T0 
differed between the EXP and CTRL groups, indicating the 
homogeneity of the study sample. miR-124-3p and miR-
637 remained undetectable in both groups during the entire 
study period. In EXP, miR-21-5p was neither affected 
by the intervention nor differed from CTRL at any time 
point. A similar trend was noted for miR-23a-3p and miR-
24-3p: the levels were decreased between T0 and T1 by 
about 20% (p < 0.01) and 70% (p < 0.001), respectively, 
and at T2 by about 20% and 50%, respectively (p < 0.05 
for both). Moreover, the levels were lower compared to 
those measured in CTRL at T1 (p < 0.05 and p < 0.001, 
respectively) and T2 (p < 0.001 for both). miR-100-
5p showed the highest variability in both groups: it was 
slightly decreased in EXP at T2 compared to T0 (p < 0.05). 
miR-122-5p and miR-148a-3p were decreased (50% and 
30%, respectively) in EXP at T1 as compared to T0 (p < 
0.05 and p < 0.01, respectively) but returned to baseline at 
T2 (p < 0.05, compared to T1). miR-125-5p was decreased 
by half in EXP at T1 as compared to T0 (p < 0.01) although 
with no difference compared to CTRL. miR-93-5p was 
the only miRNA that increased in EXP, with a two-fold 
increase measured at T1 as compared to T0 (p < 0.001) 
and CTRL at T1 (p < 0.01); however, at T2 it returned to 
baseline (p < 0.001 compared to T1).
No changes in either biochemical marker of bone 
turnover, OPN and OPG, were observed (Figure 2). DKK1 
was significantly decreased by one fourth in EXP at T1 as 
compared to T0 (p < 0.05) but returned to baseline value 
at T2. DKK1 at T1was also lower in EXP than in CTRL 
(p < 0.05), as seen for OCN, which was significantly 
decreased in EXP at T1 (p < 0.01), although the difference 
was not significant compared to CTRL. SOST, instead, was 
significantly decreased in EXP at T2 as compared to T0, and 
also as compared to CTRL at the same time point (p < 0.05). 
No changes in inflammatory cytokines and bone metabolism-
regulating hormones were observed in EXP (Figure 3).
In EXP, SOST changes were significantly, although 
slightly, inversely correlated with miR-93-5p and miR-
122-5p (r = –0.38, r = –0.35, respectively; p < 0.05) as 
well as OPG with miR-100-5p and miR-122-5p (r = –0.38, 
r = –0.34, respectively; p < 0.05). OPG and miR-122-5p 
were also correlated, although directly, in CTRL (r = 0.71; 
p < 0.05). In CTRL, OCN was directly correlated with 
miR-93-5p (r = 0.40; p < 0.05), miR-100-5p (r = 0.39; 
p < 0.05), miR-125-5p (r = 0.47; p < 0.01), miR-148a-3p 
(r = 0.62; p < 0.001),but these trends were lost in EXP.
DISCUSSION
We investigated the effect of an RS training program 
on the profile of a panel of free circulating miRNAs whose 
levels have been associated with increased risk of bone 
fracture. Our results show that an 8-week RS training 
protocol was able to modify the levels of circulating 
miRNA associated with fracture risk. The kinetics of 
response differed: miR-23a-3p, miR-24-3p, and miR-100-
5p showed a net decrease by the end of the 8 weeks, while 
other miRNAs were only transiently modified (i.e., miR-
122-5p, miR-125-5p, miR-148a-3p, miR-93-5p). Moreover, 
contrary to previous findings on cohorts of elderly subjects, 
some miRNAs associated with bone cell function, i.e., 
miR-124-3p [28–30] and miR-637 [25, 31, 32] were 
undetectable in our population.
The metabolic markers of bone turnover were only 
minimally affected, and only those responsive to load (e.g., 
DKK1, SOST, and OC) showed a response. Comparably, 
the set of cytokines and endocrine markers, which are 
considered highly sensitive to exercise interventions [6], 
were completely unaffected.
The selected panel of miRNAs comprises a series 
of miRNAs involved in osteoblastogenesis and/or 
osteoclastogensis, in bone cell function, and/or clinically 
relevant because associated with BMD and bone fracture 
risk. Seeliger et al. [20] identified specific miRNAs 
differentially expressed in patients with osteoporotic vs. 
non-osteoporotic fractures. Nine miRNAs (i.e., miR-21, 
miR-23a, miR-24, miR-93, miR-100, miR-122a, miR-
124a, miR-125b, and miR-148a) were upregulated in the 
serum of patients with osteoporosis and 6 miRNAs (i.e., 
miR-21, miR-23a, miR-24, miR-25, miR-100, and miR-
125b) were upregulated in the bone tissue of osteoporotic 
patients. Among the 5 miRNAs (miR-21, miR-23a, 
miR-24, miR-100, and miR-125b) upregulated in both 
serum and the bone tissue, Panach et al. [33] identified 
miR-122a-5p, mir-125b-5p, and miR-21-5p as markers 
for osteoporotic fractures. Given that they are clinically 
relevant in cohorts of elderly subjects, modulating their 
expression earlier in life via specific physical activity 
protocols, for example, could be an effective strategy 
for improving bone health [8]. From a health prevention 
perspective, RS training might offer an acceptable form of 
time-saving and high-intensity physical activity.
miR-21-5p, miR-122-5p, and miR-125p have been 
positively associated with osteoporotic bone fractures and 
serum cross-laps concentrations (CTx-I), independent of 
age [33]. Recently, miR-24-3p, one of the most affected 
miRNAs in our setting, was found to be highly negatively 
associated with BMD in osteoporotic patients, together 
with miR-21-5p, miR-93-5p, miR-100-5p, and miR-
125-5p [34]. Indeed, miR-24 and miR-23a, within the 
miR-23a-24-27a cluster, inhibit osteoblast differentiation 
by inhibiting Runx2 via SATB2 inhibition [35]. 
Moreover, miR-23a-3p and miR-24-3p inhibit osteogenic 
differentiation by targeting Runx2 and CXCL-12 [36] and 
Tcf-1 [37], respectively. Yavropoulou et al. [38], however, 
recently reported an inverse association between miR-23a 
(and miR-21-5p, miR-124-3p) and osteoporosis severity 
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in post-menopausal osteopenic subjects and osteoporotic 
patients with at least one vertebral fracture.
miR-100, another miRNA that displayed differential 
behavior between the EXP and the CTRL groups, is 
known to be involved in BMP-dependent mechanisms 
involved in the fate of mesenchymal stem cells towards 
osteoblastogenesis [39, 40]. Finally, among the miRNAs 
in which a decrease was noted for the EXP group, 
miR-148a-3p was found to be involved in hedgehog 
signaling as an inhibitor of osteoblast differentiation of 
mesenchymal stem cells [41]. miR-93, instead, which was 
seen to increase during the first half of the 8-week study, 
other than being negatively associated with BMD [34] has 
also been associated with inhibited osteoblastogenesis in 
humans and mice [42, 43].
The mechanism by which changes in circulating 
levels of fracture risk-associated miRNA occur after RS 
training is unknown. However, based on the changes in 
protein marker concentrations (i.e., DKK1 and SOST), 
we may speculate that direct biomechanical stimulation 
(i.e., ground reaction force plus muscle traction) might be 
the main one. Indeed, DKK1 and SOST are the effectors 
of the mechanosensitive function of bone tissue: their 
decrease during RS training indicates an increasing load 
[44, 45]. On the contrary, it seems rather unlikely that the 
changes in these miRNAs are dependent upon metabolic 
or inflammatory changes, since we did not observe any 
changes in the relative markers. Only miR-21 was listed 
in a proposed panel of mechanosensitive miRNAs [46]. 
The correlation analysis indicates an inverse interaction 
Figure 2: Changes in metabolic markers of bone turnover. The figure shows the changes in the profile of serum levels of 
metabolic markers of bone turnover in the experimental group (orange blocks) and the controls (violet blocks). Blocks indicate the ranges, 
central lines indicate the mean values. Asterisks indicate significant intergroup differences at a specific time point (*p <  0.05). Symbols on 
bars indicate within-group difference vs. T0 ($p <  0.05; $$p <  0.01). DKK1: Dikkopf 1; SOST: sclerostin; OPG: osteoprotegerin; OCN: 
osteocalcin; OPN: osteopontin.
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between miR-93-5p/miR-122-5p and sclerostin as well as 
between miR-100-5p/miR-122-5p and OPG suggesting a 
possible role for these miRNAs in mechanosensitity and 
osteoimmune crosstalk. Noteworthy, the direct association 
between OPG and miR-122-5p as well as the direct 
correlation between OCN and miR-93-5p, miR-100-5p, 
miR-125-5p, and miR-148a-3p only in CTRL suggest that 
the possible underlying regulatory mechanisms acting 
under resting conditions, are instead uncoupled by RS 
training.
The mechanosensitivity of miRNA is a fresh 
research topic, and further studies are still needed. 
Nonetheless, mechanosensitive involvement of at least 
some of the miRNA studied here cannot be excluded, 
however this hypothesis has not still been tested. Indeed, 
of the assayed miRNA none have been previously 
specifically associated with the serum levels of bone 
markers. Contrarily, all of them have been associated 
with either inflammatory (IL-1β, TNFα) or metabolic 
(leptin, insulin) markers although in specific pathological 
conditions [47].
A specific miRNA signature in osteoporosis and 
fracture risk is desirable, since it would open the way to 
developing novel diagnostic/prognostic biomarkers and 
support existing diagnostic tools, DXA, and bone turnover 
markers. This is desirable since both approaches have 
considerable limitations [19, 48–51]. The signatures are, 
at least in part, known for cardiac and neoplastic diseases 
[52] but not for metabolic diseases of bone. Given the 
putative association of circulating miRNAs with fracture 
Figure 3: Changes in fracture inflammatory cytokines and bone metabolism-associated hormones. The figure shows 
the changes in the profile of serum levels of cytokines (interleukin (IL)-1β, tumor necrosis factor (TNF)α), and hormones (leptin, insulin, 
parathyroid hormone [PTH]) associated with bone metabolism and fracture risk in the experimental group (orange blocks) and the controls 
(violet blocks). Blocks indicate the range, central lines indicate the mean values. None of the comparisons was found to be statistically 
significant.
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risk, we thought it was interesting to study their response 
to a specific training protocol. This is because a study on 
females recently demonstrated that a school-based high-
intensity physical activity represents an effective strategy 
for both improving peak bone mass and preventing age-
dependent bone loss [8].
In recent literature, studies on the effects of different 
physical activity protocols on the circulating levels of 
different panel set of miRNAs are abundant, as reviewed 
in [53, 54]. The short-term, or even acute, response of 
miRNA to exercise has been highlighted by previous 
studies, thus supporting our findings, although on different 
sets of miRNA. Eight-week-long explosive strength 
training (EXPL), hypertrophic strength training (HYP), 
and high-intensity interval training (HIIT) in trained 
subjects, for example, had similar inhibitory effects on 
four miRNAs (miR-16, miR-21, miR-93 and miR-222) 
and the baseline levels of miR-93 independently predicted 
the isometric extension of the leg [55]. In an experimental 
setting similar to ours, 4-to-6 sprints, 3 times per week 
over 6 weeks decreased the circulating levels of 4 miRNA 
associated with muscle development (myo-miRNA: miR-
1, miR-133a, miR-133b, miR-486) [56]. Very recently, 
the miRNA response following an half-marathon was 
studied, with a particular focus on miR-133 and miR-206 
that increased parallel with the increase of the biomarkers 
of nonspecific tissue damage [57].
The circulating miRNA profile reflects intracellular 
miRNA expression and can serve as marker of the 
biological processes taking place in cells. Owing to 
their place in the hierarchical process leading to gene 
expression just before the translation of the genetic code 
into a protein, as fine-tune modulators, the information 
deriving from their circulating levels may eventually 
predict an early biological response to a specific condition 
[23, 58].
A possible limitation is that, although the levels of 
the circulating miRNAs selected for this study have been 
associated with fracture risk, they do not necessarily mark 
a bone metabolic process since, under the experimental 
conditions analyzed here, they could be produced by many 
other cell types. However, despite the multiple targets of 
each single miRNA, this study evidences that some of 
those miRNAs whose high circulating levels have been 
associated with an increased fracture risk are actually 
reduced by a specific protocol of physical activity. It is 
plausible that RS training has positive effects on bone 
metabolism, although the current setting did not allow us 
to investigate the role of intermittence. Furthermore, our 
study demonstrated that miRNAs, as key regulators of 
cellular functions, respond to stimuli much more sensibly 
than classical biochemical markers, and that circulating 
miRNAs may mark an early response to a physiological 
or pathological stimulus [23]. However, the lack of any 
previous information about the association between the 
assayed miRNA and the bone markers here considered 
should be highlighted. Hence, either a direct inter-
dependency or a co-consequence of the same stimulus 
might be hypothesized.
To this end, the study of the physiological response 
of miRNAs, particularly to exercise protocols, holds 
importance because it may help to improve current 
knowledge and limit our uncertainty about the physiological 
role of these mediators/markers. To our knowledge, this is 
the first study to explain the modifications in the circulating 
levels of a panel of fracture-risk associated miRNAs to a 
specific exercise protocol.
In conclusion, our findings demonstrate that brief, 
supramaximal running training in young males can reduce 
the circulating levels of some of the miRNA that have 
been associated with fracture risk in elderly populations. 
This supports the hypothesis for a potential preventive role 
of such exercise training against osteoporosis.
MATERIALS AND METHODS
Participants
This randomized, controlled longitudinal 
experimental protocol was part of a larger study 
investigating cardiovascular, metabolic, inflammatory, 
and bony adaptations after a RS training protocol [17]. 
In accordance with the Declaration of Helsinki, all 
subjects were informed about the procedures, benefits, 
and possible adverse events associated with the protocol 
and they gave their written, consent. The protocol was 
approved by the Comitato EticoOspedale San Raffaele 
(Milan, Italy). 
The study cohort consisted of 18 healthy, physically 
active male adults. Sample size was calculated based on 
the requirements of the previous study [17]. Inclusion 
criteria were: no history or current clinical signs of 
cardiovascular, pulmonary, metabolic or bone diseases; 
no traumatic fractures in the 2 previous years; no routine 
involvement in intermittent sports (e.g., soccer, handball, 
basketball); physical activity below the moderate level 
according to American College of Sports Medicine 
(ACSM) guidelines (i.e., a minimum of 30 min of aerobic 
activity, 5 times a week [59]). Participants were randomly 
assigned to the experimental group (EXP) that performed 
RS training or the control group (CTRL) that performed 
normal, daily physical activities, as described in [17]. 
The two groups were comparable for anthropometric 
characteristics (Table 1).
Experimental protocol
Test session
A test session was performed 1 week before the 
beginning of RS training to familiarize the subjects with 
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the experimental protocol. Testing, as well as the following 
experimental phase, was performed on a synthetic 
indoor track at a constant temperature of 18–20° C. 
The test entailed five 30 m sprints interspersed by 25 s 
of active recovery [17, 60]. Before each test session, the 
subjects completed a 10 min warm-up of low-intensity 
running and striding, followed by three submaximal 30 m 
sprints with 120 s of active recovery that served to (re-)
accustom them to the testing procedures. Then, each 
subject completed a preliminary, single 30 m sprint test. 
This trial served to avoid adoption of protective pacing 
strategy and to have a criterion score for the subsequent 
5 × 30 m sprint test. Specifically, in case the performance 
time for the first sprint of the RS test was > 2.5% than 
the criterion score, the test was terminated and the RS 
test had to be repeated, after a 5 min rest, with greater 
effort [17, 61]. Five seconds before starting each sprint, 
the participants assumed the standardized ready position 
[62], and waited for the start signal from the countdown 
given by the researcher.
The subjects were asked to maintain their usual 
eating habits throughout the duration of the protocol, 
but were told to refrain from caffeine and alcohol intake 
during the 12 h preceding a test session.
RS exercise
RS exercise consisted of 18-times repeated 15 m 
sprints with 17 s of passive recovery [13, 17], after each 
bout the subjects ran in the opposite direction. Each set 
of exercise, lasting 6 min, was repeated 3 times a week, 
with at least a 48 h recovery between each test. Before 
each training session, a 10 min warm-up of low-intensity 
running and striding, was performed by the subjects, 
followed by 3 submaximal 15 m sprints with 60 s of 
passive recovery that served to (re-)accustom them to the 
experimental procedures. The protocol lasted 8 weeks and 
a total of 24 RS sessions were performed by each subject 
of the EXP group. A schematic illustration of the protocol 
is shown in Figure 4.
Figure 4: Experimental protocol scheme. 18 subjects were randomly assigned to either an experimental (EXP, orange) or a control 
(CTRL, violet) group. EXP (n = 9) performed 18 maximal all-out 15 m sprints with 17 s of passive recovery, 3 times/week, over 8 weeks. 
CTRL (n = 9) carried out normal daily activities for 10 weeks. Blood was sampled in both groups before the start of the protocol (T0), at 4 
weeks (T1), and then the week after completion of the 8 week training period (T2).
Table 1: Anthropometric features of the study population
EXP (n = 9) CTRL (n = 9)
Age (years) 24.3 ± 3.7 23.8 ± 4.4
Height (m) 1.78 ± 0.07 1.83 ± 0.07
Body mass (kg) 69.9 ± 5.8 73.0 ± 7.2
BMI (kg/m2) 22.1 ± 1.7 21.8 ± 1.1
Data are expressed as mean ± SD. BMI: body mass index.
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Blood sampling and testing
Blood sampling
Blood samples were taken from all subjects at 
baseline, before the start of the protocol (T0), after the 
end of the 4th week (after the 12th RS session, T1), and 
the day after the end of the protocol (after the end of the 
8th week (i.e., after the 24th RS session) T2). Blood was 
collected in the morning after overnight fasting, between 
8:00 and 9:00 by standard antecubital venipuncture in 
K2EDTA spray-coated (Vacutainer, Becton Dickinson & 
Co., Franklin Lakes, NJ, USA) and serum SSTII Advance 
(Becton Dickinson & Co.) tubes. After collection, the 
tubes were inverted at least 10 times (EDTA tubes were 
also homogenized for 15 min), stored upright at 4° C, 
and brought to the laboratory. Plasma and serum were 
separated by centrifuging whole blood at 1300 g for 10 min 
at 15° C and then aliquoted in plain apyrogen DNase/
RNase-free tubes (Eppendorf AG, Hamburg, Germany). 
Plasma aliquots for miRNA analyses were further 
centrifuged at 300 g for 5 min at room temperature (RT, 
22° C). The supernatant was transferred to a new plain 
tube and stored at –80° C until assayed. The pre-analytical 
phase strictly adhered to standard [2] and circulating 
miRNA-specific [23] precautions.
Circulating miRNA analyses
MicroRNA-enriched total RNA was extracted from 
plasma with a miRCURY™ RNA Isolation Kit (Exiqon 
A/S, Denmark). Extraction efficiency was checked 
through 3 synthetic oligonucleotides (spike-ins: Sp2, Sp4, 
Sp5) added at recommended concentrations. Reverse 
transcription and real-time PCR were performed with a 
miRCURY LNA™ Universal RT microRNA PCR and 
Universal cDNA synthesis kit II (Exiqon), using Sp6 and 
Cel39 as internal controls. Real-time PCR was performed 
using specific miRCURY LNA™ microRNA PCR primers 
(Exiqon; Supplementary Table 1). The following panel of 
fracture risk-associated circulating miRNAs was tested: 
miR-21-5p, miR-23a-3p, miR-24-3p, miR93-5p, miR-100-
5p, miR-122-5p, miR-124-3p, miR-125b-5p, miR-148a-
3p, miR-637. Relative expressions were calculated by the 
2–ΔΔCT method. miR-425-5p and miR-484 were chosen as 
housekeeping since they result to be more stable in this 
setting. Hemolysis was checked by calculating the miR-
23a-to-miR-451 ΔCT ratio: a value greater than 7 was 
considered as indicative of hemolysis [63].
Biochemical markers analyses
A panel of biochemical markers associated with 
either bone or energy metabolism was measured in serum 
to test for possible metabolic established effects of the 
training protocol. The biomarkers were tested through a 
Milliplex® multiplex immuno-based fluorescent Luminex 
®assay (EMD Millipore, Billerica, MA, USA) on a 
Luminex MagPix® system (Bio-Rad Laboratories, Hercules, 
CA, USA). Briefly, the assay allows the measurement of 
multiple analytes within the same well, containing the same 
sample aliquot through the addition of magnetic fluorescent 
beads coated with antibodies against the specific analyte of 
interest, thus completely avoiding inter-assay variability. 
The analytes, and the relative intra- (CVw) and inter-
assay (CVb) variability, were: interleukin (IL)-1β (7%, 
9%), tumor necrosis factor (TNF)-α (8%, 7%), DKK-1, 
sclerostin (SOST; 6%, 13%), osteocalcin (OCN; 5%, 12%), 
osteopontin (OPN; 2%, 12%), osteoprotegerin (OPG; 5%, 
11%), parathyroid hormone (PTH; 4%, 9%), insulin (6%, 
8%), and leptin (5%, 11%).
Statistical analysis
Based on their parametric distribution (D’Agostino-
Pearson omnibus normality test), the parameters 
are described as mean ± SD and range. For miRNA 
analysis, T0 values for CTRL were set at 1 and used 
for normalization. Within-group time-dependent 
modifications were analyzed by repeated one-way 
ANOVA for paired samples and post hoc Bonferroni’s 
test. Between-group differences, at each time point, were 
analyzed with the unpaired t test.
The correlations between miRNA and bone markers 
trends over the time was tested with the Spearman’s rank 
correlation test.
Statistical analysis was performed using Prism 
v6.01 (GraphPad Software, Inc., La Jolla, CA, USA). 
Comparisons were considered statistically significant 
when p < 0.05.
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